$430 Million is the total value of Aisling Capital LLC's 18 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | LOXO ONCOLOGY INC | $129,409,000 | +22.7% | 4,028,920 | 0.0% | 30.09% | +38.5% | |
| ZLTQ | ZELTIQ AESTHETICS INC | $70,056,000 | +11.0% | 1,609,727 | 0.0% | 16.29% | +25.2% | |
| AIMT | AIMMUNE THERAPEUTICS INC. | $61,146,000 | +36.3% | 2,990,000 | 0.0% | 14.22% | +53.8% | |
| VSAR | VERSARTIS INC | $37,615,000 | +21.6% | 2,524,465 | 0.0% | 8.74% | +37.3% | |
| VRAY | VIEWRAY INC. | $23,415,000 | -30.8% | 7,480,887 | 0.0% | 5.44% | -21.8% | |
| ESPR | ESPERION THERAPEUTICS INC. | $20,497,000 | -9.6% | 1,637,125 | 0.0% | 4.76% | +2.0% | |
| ADMA | ADMA BIOLOGICS INC | $18,474,000 | -29.4% | 3,608,171 | 0.0% | 4.30% | -20.3% | |
| TTOO | T2 BIOSYSTEMS INC | $14,891,000 | -27.3% | 2,830,992 | 0.0% | 3.46% | -18.0% | |
| TRXC | TRANSENTERIX INC. | $10,837,000 | -23.1% | 8,335,819 | 0.0% | 2.52% | -13.2% | |
| CDTX | CIDARA THERAPEUTICS INC. | $10,620,000 | -9.2% | 1,021,148 | 0.0% | 2.47% | +2.5% | |
| AGRX | Sell | AGILE THERAPEUTICS INC | $10,288,000 | -35.2% | 1,804,933 | -20.7% | 2.39% | -26.9% |
| PRTK | PARATEK PHARMACEUTICALS INC | $7,433,000 | +18.4% | 482,680 | 0.0% | 1.73% | +33.5% | |
| SYRS | SYROS PHARMACEUTICALS, INC. | $6,184,000 | -12.3% | 508,565 | 0.0% | 1.44% | -1.0% | |
| CEMP | CEMPRA INC | $3,341,000 | -88.4% | 1,193,060 | 0.0% | 0.78% | -86.9% | |
| XENT | Sell | INTERSECT ENT INC | $2,723,000 | -30.8% | 225,000 | -9.5% | 0.63% | -21.9% |
| CMRX | CHIMERIX INC. | $2,176,000 | -16.9% | 472,943 | 0.0% | 0.51% | -6.3% | |
| PERNIX THERAPEUTICS HLDGS INCdebt | $625,000 | -7.4% | 2,500,000 | 0.0% | 0.14% | +4.3% | ||
| PTXTQ | New | PERNIX THERAPEUTICS HLDGS IN | $407,000 | – | 210,000 | +100.0% | 0.10% | – |
| EVAR | Exit | LOMBARD MED INC | $0 | – | -443,182 | -100.0% | -0.09% | – |
| PTX | Exit | PERNIX THERAPEUTICS HLDGS IN | $0 | – | -2,010,000 | -100.0% | -0.26% | – |
| CYNA | Exit | CYNAPSUS THERAPEUTICS INC. | $0 | – | -1,121,381 | -100.0% | -9.29% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.